Skip to main content
GKB logo

GKB — Investor Relations & Filings

Ticker · 1707 ISIN · TW0001707008 TW Manufacturing
Open in API
Filings indexed 2,129 across all filing types
Latest filing 2026-05-26 Declaration of Voting R…
Country TW Taiwan
Listing TW 1707

About GKB

http://www.grapeking.com.tw

Grape King Bio Ltd. is a biotechnology firm specializing in the research, development, and production of health supplements and functional beverages. Established in 1969, the company has evolved into a prominent provider of probiotics, energy drinks, and nutritional products tailored for diverse age groups. It operates a dedicated Biotech Research Institute staffed by over 160 specialists, focusing on proprietary fermentation technology and innovative formulations that have garnered over 170 international awards. The company offers a comprehensive one-stop OEM/ODM platform, providing integrated manufacturing services across various dosage forms. Guided by the philosophy of "Technology, Health, and Hope," Grape King Bio serves global markets through its own brands and strategic subsidiaries, emphasizing high-quality standards and advanced biotechnological applications to enhance consumer well-being.

Recent filings

Filing Released Lang Actions
公告本公司115年股東常會重要決議事項
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is an official public disclosure by Grap King Biotech of the resolutions passed at its 115th regular shareholders’ meeting, listing vote outcomes on profit distribution, approval of financial statements, etc. This matches “Declaration of Voting Results & Voting Rights Announcements” (DVA). It is not the full meeting materials, but the announcement of voting results.
2026-05-26 Chinese
115年05月僑外投資持股
Regulatory Filings Classification · 85% confidence The document is a routine disclosure file from Taiwan’s Market Observation Post System reporting aggregate foreign and mainland China investor shareholdings by the company (證券代號 1707). It does not report a specific management change, financing event, earnings, or AGM materials. It is a standard regulatory filing that does not fit specialized categories such as major individual insider holdings (DIRS/MRQ) or capital changes. Therefore, it is best classified under General Regulatory Filings (RNS).
2026-05-13 Chinese
115年第1季財務報告書 — 202601_1707_AI1.pdf
Interim / Quarterly Report Classification · 96% confidence The document is titled “合併財務報告暨會計師核閱報告” and covers the first quarter (民國115年及114年1月至3月) for 葡萄王生技股份有限公司. It includes full interim financial statements (balance sheet, income statement, cash flows, equity, and extensive notes) prepared under IAS 34 “Interim Financial Reporting,” along with the auditor’s review report. This matches the definition of an Interim / Quarterly Report (IR), not merely an announcement or standalone audit opinion. Q1 2026
2026-05-12 Chinese
115年第1季海外子公司投資
Interim / Quarterly Report Classification · 90% confidence The document is from Taiwan’s Market Observation Post System (公開資訊觀測站) for Grape King Biotech showing detailed financial tables for the first quarter of Year 115 (ROC calendar). It contains substantive financial data (equity-method investment amounts, percentages, and recognized profit/loss) for Q1. This is part of the company’s interim/quarterly report rather than a summary earnings release or announcement. Therefore, it should be classified as an Interim/Quarterly Report (IR). Q1 2026
2026-05-12 Chinese
115年第1季大陸投資
Regulatory Filings Classification · 70% confidence The document is a standalone regulatory compliance schedule (“大陸被投資公司資訊表”) provided via Taiwan’s公開資訊觀測站 for Q1 (年度115季別01), detailing cross‐strait investment balances, shareholdings, and fund remittances. It does not include full financial statements or narrative analysis as found in a quarterly (IR) report, nor is it an earnings headline (ER) or other specific category. This kind of one‐table regulatory disclosure is best classified under the general Regulatory Filings category.
2026-05-12 Chinese
115年第1季權益變動表
Interim / Quarterly Report Classification · 90% confidence The document is the actual consolidated Statement of Changes in Equity for the first quarter (民國115年第1季) containing detailed financial data (equity account balances, movements, totals). This is part of a quarterly/interim financial report, not merely an announcement or summary. Therefore it fits the Interim / Quarterly Report category (IR). Q1 2026
2026-05-12 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.